I migliori Anemia Emolitica per il trattamento di Anemia Emolitica - TOP-6 medici

Il professor Zafer Gülbaş — ematologo-oncologo, fondatore e direttore del Centro Trapianti di Midollo Osseo dell'Anadolu Medical Center, che è tra i più grandi in Europa.

Perché i pazienti scelgono e si fidano del Dr. Gülbaş:

• Ha creato il Centro Trapianti di Midollo Osseo dell'Anadolu "da zero"; nel centro sono stati eseguiti 3.000+ trapianti (dal 2010).
• 81% di successo nei trapianti autologhi — un alto tasso secondo i dati del centro.
• Formazione internazionale: tirocini e lavoro nei centri leader — Hadassah (Israele), Fred Hutch e MD Anderson (USA), Princess Margaret (Canada).
• 260+ pubblicazioni scientifiche e 5.000+ citazioni — confermano il significativo contributo del professore nella trapiantologia.
• La clinica Anadolu — partner ufficiale di Johns Hopkins Medicine International, che garantisce accesso a protocolli internazionali, consili medici e controllo di qualità.
• Gestisce i casi più complessi: leucemie, linfomi, anemia aplastica, coagulopatie (disturbi della coagulazione).

Prof. Amos Toren, MD, PhD, MHA, is a pediatric hemato-oncologist and BMT specialist. He served as Director of Pediatric Hemato-Oncology and BMT at Sheba Medical Center.

He is board certified in Pediatrics, Pediatric Hemato-Oncology, and Bone Marrow Transplantation. He holds a PhD in Human Genetics. He was Head of the Hematology Division at Tel Aviv University for two terms. He is a member of ASH, COG, ESPHI, EBMT, and CIBMTR. He also serves on the Ministry of Health Cord Blood Committee.

He led one of Israel’s most advanced pediatric oncology and BMT programs. The program treated children and young adults. His focus includes leukemia and lymphoma, immunodeficiencies, and rare cancers. He specializes in BMT and CAR T-cell therapy.

His translational research covers CAR T cells, cytokine-induced killer cells, pediatric brain tumors, and targeted therapies. He has worked with St. Anna, the NIH, and St. Jude. His publications include studies on pediatric SCT prophylaxis and PARP resistance.

Dr. Hana Golan, MD, heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation (BMT) Division at Sheba Medical Center. She specializes in childhood cancers, with a focus on neuroblastoma and other high-risk solid tumors.

She leads one of the region’s most advanced pediatric oncology programs. She manages complex, high-risk cases and practices at a hospital ranked in the global top 10.

She is the principal investigator of the High-Risk Neuroblastoma ESIOP protocol. She serves as an investigator in international Phase I/II trials and as the national coordinator of multicenter oncology protocols. She led the development of computerized chemotherapy protocols and patient databases to improve safety.

She earned her MD from the Technion. She completed residencies in pediatrics and pediatric hemato-oncology at Sheba. She conducted advanced research in transplantation immunology at the Weizmann Institute. She is board-certified in Pediatrics and Pediatric Hematology-Oncology. She is a Senior Lecturer at the Sackler Faculty of Medicine, Tel Aviv University. Her research focuses on cancer stem cells, targeted therapies, treatment-resistant malignancies, and cannabinoid-related oncology.

Dr. Abraham Avigdor, MD, is Director of the Institute of Hematology and Co‑Director of the Hematology & Bone Marrow Transplantation Division at Sheba Medical Center. He is an international leader in lymphoma, CAR‑T, and advanced hemato‑oncology with more than 35 years of experience. His clinical focus includes lymphomas, multiple myeloma, and complex blood cancers.

He is a pioneer in CAR‑T integration. He leads cellular therapy and bone marrow transplantation programs (autologous and allogeneic). He also advances stem cell therapies and precision diagnostics, including PET/CT‑based prognostics. His work includes immunotherapy and targeted regimens and the development of innovative, data‑driven protocols.

He collaborates with LYSA, EMCL, and international PET groups. He has authored more than 130 publications. Key roles include Founder and President of the Israeli Lymphoma Working Group, former Chair of the Israeli Lymphoma Study Group, and Senior Lecturer at Tel Aviv University. Education: MD, Ben‑Gurion University; residency, Sheba Medical Center; postdoctoral fellowship, Weizmann Institute. Awards include the Knesset Prize, the Israeli Ministry of Health Award, and the Sackler Prize.

Prof. Avichai Shimoni, MD, is Director of Bone Marrow Transplantation at Sheba Medical Center. He is a hemato-oncologist with over 30 years of experience in bone marrow transplantation, cellular therapies, and advanced blood cancer care.

He leads a high-volume program for complex, high-risk blood cancers. He performs allogeneic and autologous transplants. He also provides CAR T-cell therapy for leukemia, lymphoma, and multiple myeloma. He completed a bone marrow transplantation fellowship at MD Anderson Cancer Center.

He is Chairman of Hematology at Tel Aviv University and a Professor of Hematology. He has authored more than 250 scientific papers. His research focuses on CAR T-cell therapy and stem cell transplantation. He is often listed among Israel's Best Doctors (Forbes 2025 and 2026).

Il medico è un ematologo pediatrico altamente esperto, specializzato nella diagnosi e nel trattamento dei disturbi del sangue nei bambini. Con oltre 15 anni di esperienza clinica, il medico ha contribuito in modo significativo ai progressi nell'ematologia pediatrica, concentrandosi su condizioni come anemia, disturbi della coagulazione e leucemia. Il medico è certificato e ha pubblicato numerosi articoli di ricerca su riviste mediche leader. Inoltre, il medico è coinvolto in diversi studi clinici mirati a migliorare i risultati del trattamento per i pazienti pediatrici.<\/p>